Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
LENSAR, Inc. (Nasdaq: LNSR) has announced that CEO Nick Curtis will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with the presentation available on-demand from 7:00 a.m. Eastern Time. The webcast can be accessed through the company's website and will remain available for one month following the event. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, aiming to improve surgical outcomes through innovative technology.
LENSAR, a global medical technology leader in femtosecond laser surgical solutions for cataracts, announced CEO Nick Curtis will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET and can be accessed through the Company's website. LENSAR specializes in advanced laser systems designed to improve visual outcomes and efficiency in cataract surgery.
LENSAR, Inc. (Nasdaq: LNSR) reported significant financial growth for Q2 2021, achieving a 57% increase in total revenue to $7.9 million compared to Q2 2020, driven by a 70% rise in procedure volume. The company’s recurring revenue rose to 90%, up from 78% the previous year. Despite this growth, LENSAR recorded a net loss of $4.4 million, slightly improved from a loss of $4.5 million in Q2 2020. R&D expenses surged by 110% to $3 million, reflecting continued development of the ALLY system, expected to launch in 2022. The company maintained a cash position of $34.6 million.
LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2021 financial results on August 5, 2021, before market open. A conference call and webcast will follow at 8:30 am ET on the same day to discuss the results and recent corporate highlights. LENSAR specializes in advanced femtosecond laser surgical solutions for cataract treatment, utilizing proprietary technologies aimed at enhancing surgical outcomes and efficiency.
LENSAR, Inc. (NASDAQ: LNSR) announced the acceptance of 12 abstracts showcasing its advanced femtosecond laser technology at the 2021 ASCRS Annual Meeting from July 23-27 in Las Vegas. The company will also demonstrate its next-gen ALLY™ Adaptive Cataract Treatment System, with a 510(k) application expected in Q1 2022 and a commercial launch planned for later that year. CEO Nick Curtis emphasized the significance of these presentations in validating LENSAR's innovations and improving patient outcomes in cataract surgeries.
LENSAR, a global medical technology company focused on femtosecond laser solutions for cataract treatment, announced that CEO Nick Curtis will present at the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021. The presentation will be available on-demand starting at 8:00 a.m. ET on the company's website and accessible for two weeks thereafter.
The LENSAR Laser System aims to enhance surgical outcomes with advanced imaging and efficient design, targeting cataracts and astigmatism management.
LENSAR, Inc. (LNSR) reported financial results for Q1 2021, with total revenues reaching $7.0 million, a 19.3% increase from $5.9 million in Q1 2020. This growth is attributed to enhanced sales of LENSAR Laser Systems and procedure licenses, particularly in the U.S. However, the net loss widened to $5.2 million ($0.56 per share) compared to $3.7 million in the previous year. The company anticipates launching its next-generation system, ALLY™, with a 510(k) filing expected in 2022. As of March 31, 2021, LENSAR held $35.9 million in cash, down from $40.6 million at the end of 2020.
LENSAR, Inc. (NASDAQ: LNSR) will release its first quarter 2021 financial results on May 5, 2021, prior to market opening. The company specializes in advanced femtosecond laser surgical solutions for cataracts and will host a conference call at 8:30 am ET on the same day to discuss these results and recent corporate highlights. Interested participants can join via telephone or access the live webcast on LENSAR's website. The company is committed to enhancing visual outcomes with its proprietary LENSAR Laser System.
LENSAR, Inc. (LNSR) reported fourth quarter 2020 revenue of $8.3 million, a slight decline of 2.1% from $8.5 million in Q4 2019, primarily due to COVID-19 impacts. Yearly revenue fell 13.6% to $26.4 million. Selling, general, and administrative expenses rose 77.8% to $8.7 million in Q4, largely due to stock-based compensation. The net loss for Q4 was $6.8 million, increasing from $2.5 million a year prior. Despite challenges, LENSAR increased its laser system base by 10% and plans to submit a 510(k) application for its ALLY system by Q1 2022, aiming for a launch later in the year.
LENSAR, Inc. (NASDAQ: LNSR) will announce its fourth quarter and full year 2020 financial results on March 10, 2021, before market open. A conference call and webcast will follow at 8:30 am ET that day to discuss the results and corporate updates. LENSAR specializes in advanced femtosecond laser systems for cataract treatments, incorporating proprietary technologies aimed at enhancing surgical efficiency and visual outcomes. Investors should note that forward-looking statements regarding the company's performance include inherent risks and uncertainties.